Clinical trials: Major Depressive Disorder, completed
Major Depression
Essential Fatty Acids for Major Depression
This is a research study to determine whether omega-3 fatty acid supplementation, when taken with the antidepressant medication escitalopram (Lexapro), helps to improve depressive symptoms in individuals who have major depressive…
- Trial name
- NCT00256412
- Testing
- Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Iowa
Major Depressive Disorder
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
To evaluate the efficacy of a fixed dose of SR58611A(350 mg q12) compared to placebo in patients with MajorDepressive Disorder (MDD) using escitalopram (10 mgqd) as positive control.
- Trial name
- PHOENIX (NCT00252330)
- Testing
- SR58611A
- Where
- 2 sites in United States, Canada
- Volunteers
- 476 people
- Sponsor
- Sanofi
Major Depressive Disorder
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder
Demonstrate ability of SEP-363856 to be superior to placebo as an adjunctive therapy to ADT in change from baseline in depressive symptoms (MADRS \& CGI-S) in MDD patients who had an inadequate response to prior ADT therapy.
- Trial name
- NCT05593029
- Testing
- SEP-363856
- Where
- 77 sites in United States, Bulgaria and 5 more
- Volunteers
- 929 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar II Disorder, Major Depressive Episode
Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression
The purpose of this study is to evaluate the antidepressant effectiveness of Geodon for the treatment of patients diagnosed with Bipolar II disorder who are currently experiencing a major depressive episode.
- Trial name
- NCT00237666
- Testing
- Ziprasidone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- The Medical Research Network
Major Depressive Disorder
An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder
The main purpose of this study is to evaluate the efficacy of saredutant 100mg once daily in combination with escitalopram 10mg once daily compared to saredutant placebo in combination with escitalopram 10mg once daily in…
- Trial name
- NCT00531622
- Testing
- saredutant (SR48968), escitalopram
- Where
- 6 sites in United States, Argentina and 4 more
- Volunteers
- 643 people
- Sponsor
- Sanofi
Major Depressive Disorder
Feasibility Pilot of Accelerated Stimulation With TMS for Treatment of Major Depressive Disorder (FAST-MDD)
This is a mixed-methods study that includes three steps. The first is a focus group to collect opinions and feedback about implementation of aTMS among clinicians, technicians, nurses, and other clinical staff at the St.
- Trial name
- NCT06961851
- Testing
- aTMS utilizing the MagVenture TMS device
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Minnesota
Major Depressive Disorder
Duloxetine Versus Paroxetine for Major Depression
To determine if duloxetine works just as well as paroxetine in the treatment of major depressive disorder.
- Trial name
- NCT00489775
- Testing
- Duloxetine, Paroxetine
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Eli Lilly and Company
Hypoactive Sexual Desire Disorder, Female Sexual Arousal Disorder
Effects of Early Abuse on Adult Intimate Relationships
This study is designed to help us better understand the factors that affect the sexual lives of women who have been sexually mistreated during childhood.
- Conditions
- Hypoactive Sexual Desire Disorder, Female Sexual Arousal Disorder, Female Orgasmic Disorder, Major Depressive Disorder
- Trial name
- NCT01803802
- Testing
- Expressive writing
- Where
- United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Childhood Trauma, Major Depressive Disorder
HPA Axis Activity Due To Early Traumatic Stress and Metabolic Symptoms
This study evaluates the association between early trauma, depression and metabolic symptoms.
- Trial name
- Cort-Metab (NCT02398877)
- Testing
- stress
- Where
- Germany
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Depressive Disorder, Major
Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
This study will evaluate the long-term safety and tolerability of rapastinel as an adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD).
- Trial name
- NCT03002077
- Testing
- Rapastinel
- Where
- 128 sites in United States
- Volunteers
- 617 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depression, Bipolar Disorder
Assessing the Impact of Self-directed Care, Within a Medicaid-funded Environment,on Participation and Community Living
This project proposed to demonstrate the effectiveness, costs, and benefits to participation and community living self-directed care programming within a financially sustainable Medicaid managed care environment.
- Conditions
- Major Depression, Bipolar Disorder, Schizophrenia
- Trial name
- NCT02520024
- Testing
- self-directed care
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Temple University Collaborative on Community Inclusion
Major Depressive Disorder
Boosting Psychotherapy Effects by Means of Transcranial Direct Current Stimulation
The present study involves the administration of three types of interventions in patients with depressive episode in the context of DDM.
- Trial name
- PSYCHOBOOST (NCT05866042)
- Testing
- tDCS
- Where
- Italy
- Volunteers
- 54 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Depressive Disorder, Major
Abilify as an Adjunctive Treatment for Refractory Depression
This is a study of the effectiveness of adding Abilify (aripiprazole), an atypical antipsychotic medication, to ongoing selective serotonin reuptake inhibitor (SSRI) antidepressant treatment for depressed outpatients who are not…
- Trial name
- NCT00220636
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Major Depressive Disorder
Intensive tDCS for MDD: Feasibility Study
This will be a prospective, open-label, single-arm study to determine the safety and feasibility of an intensive treatment of transcranial direct current stimulation (tDCS) for major depressive disorder (MDD).
- Trial name
- tDCSintensif (NCT05194267)
- Testing
- transcranial direct current stimulation (tDCS)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Major Depressive Disorder
Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder
One-third of the patients with major depressive disorder do not respond to conventional antidepressants that act through the mono-aminergic system.
- Trial name
- NCT04975100
- Testing
- Sarcosine and SSRI
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Major Depressive Disorder, Partner Relational Disorder (V61.10)
Treatment of Mood and Marriage Study (TOMMS)
The primary goal of this study is to develop and test a depression-specific marital therapy tailored for use with older adult populations.
- Trial name
- NCT00612807
- Testing
- Weekly marital therapy, As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Duke University
Cognitive Remediation, Cognitive Impairment
Internet-delivered Intervention Targeting Residual Cognitive Symptoms After Major Depressive Disorder
Background: Cognitive impairment and difficulties are frequently observed in individuals suffering from major depressive disorder. These impairments and difficulties can persist into remission as residual cognitive symptoms.
- Conditions
- Cognitive Remediation, Cognitive Impairment, Major Depression in Remission
- Trial name
- RestDep (NCT04864353)
- Testing
- RestDep: Internet-delivered intervention targeting residual cognitive symptoms
- Where
- Norway
- Volunteers
- 44 people
- Sponsor
- Haukeland University Hospital
Depressive Disorder
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of SR58611A in elderly patients with depression.The primary objective is to evaluate the efficacy of a 700 mg dose of SR58611A compared to placebo in elderly…
- Trial name
- ZEPHIR (NCT00319709)
- Testing
- SR58611A
- Where
- 5 sites in Bulgaria, Finland and 3 more
- Volunteers
- 288 people
- Sponsor
- Sanofi
Major Depressive Disorder, Depression
Investigating Predictors of Treatment Response in Treatment-Resistant Depression (TRD) With Interleaved TMS/fMRI
The purpose of this trial is identify biomarkers of response to repetitive transcranial magnetic stimulation (rTMS) in individuals with first episode or treatment resistant depression.
- Trial name
- NCT03642522
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Canada
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Major Depressive Disorder
A Phase 2 Trial of OPC-64005 for Major Depressive Disorder
The objective of the trial is to compare the efficacy of OPC-64005 at 20 mg vs placebo and to assess the safety and pharmacokinetics of OPC-64005 at 10 and 20 mg in patients with major depressive disorder (MDD).The primary…
- Trial name
- NCT04244253
- Testing
- OPC-64005 20 mg , Once-daily, OPC-64005 10 mg , Once-daily
- Where
- Japan
- Volunteers
- 273 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.